Cardiome Announces Changes to Senior Management Team

             Cardiome Announces Changes to Senior Management Team

PR Newswire

VANCOUVER, March 26, 2013

NASDAQ: CRME TSX: COM

VANCOUVER, March 26, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME)
(TSX:COM) today announces changes to the company's senior management team.
William Hunter, M.D., previously interim Chief Executive Officer and Director,
has been appointed full time President and Chief Executive Officer; Karim
Lalji has been promoted from Senior Vice President of Commercial Affairs to
Chief Commercial Officer; and Sheila Grant has been hired as Chief Operating
Officer.

"We are pleased with what Bill Hunter has accomplished in the last six  months 
including Cardiome's restructuring and managing the return of vernakalant from
our previous partner, Merck  & Co.," said Bob  Rieder, Cardiome's Chairman  of 
the  Board.  "With  Bill's  previous  experience  in  managing  a   successful 
commercial organization at Angiotech Pharmaceuticals, we have every confidence
in his leadership to move Cardiome forward as a commercial stage entity."

"Both Karim and Sheila have played pivotal roles in vernakalant's  development 
and achievements to date," said William Hunter, M.D., Cardiome's President and
CEO. "Karim's  experience in  successfully launching  pharmaceutical  products 
coupled with Sheila's extensive knowledge of vernakalant will be  instrumental 
to the company's future success."

Prior to Cardiome, Dr. Hunter co-founded Angiotech Pharmaceuticals in 1992 and
assumed the position of Chief Executive  Officer in 1997 when Angiotech was  a 
venture-stage, private, pre-clinical company with less than 50 employees.  He 
led Angiotech through 3 rounds of private equity financing, the initial public
offering and listing on the Toronto Stock Exchange and NASDAQ, over $1 billion
in equity and debt financings, a  debt restructuring and 8 separate  corporate 
acquisitions. During  that  time,  Angiotech grew  to  become  a  profitable, 
diversified, healthcare company  with over 1,400  employees, several  thousand 
commercially available products, and 12 facilities in 5 countries. Dr. Hunter,
a physician by training, served as a practicing physician in British  Columbia 
for 5 years.

Mr. Karim Lalji has served as Cardiome's SVP Commercial Affairs since 2007. As
Chief  Commercial  Officer,  he  will   be  responsible  for  overseeing   the 
commercialisation of BRINAVESS™ in Europe and other markets worldwide  amongst 
other commercial and corporate business development related activities.  Prior 
to Cardiome, Mr. Lalji was previously Vice President of Business Strategy  and 
New Product Commercialization at Sepracor, Inc. A key achievement at Sepracor,
Inc.  was  his  leadership  in   the  development  and  launch  of   Lunesta^® 
(eszopiclone) for the  treatment of insomnia.  Mr. Lalji's earlier  experience 
includes ten  years with  Merck &  Company, where  he led  several  successful 
product launches including Crixivan^® for  HIV/AIDS and Fosamax^® Once  Weekly 
for osteoporosis.  Mr. Lalji  holds a  Science Masters  in Health  and  Policy 
Management from Harvard University.

Ms. Sheila Grant was most recently Cardiome's VP of Product Development,  with 
responsibility for  the overall  management  of the  vernakalant IV  and  oral 
programs. She has  overseen the  development of vernakalant  from its  initial 
pre-clinical studies through to commercialization.  Ms. Grant's past roles  at 
Cardiome have  included Vice  President, Commercial  Affairs and  Director  of 
Business & Clinical Development. Prior to joining Cardiome, Ms. Grant acted as
business consultant to De Novo Enzyme  Corporation and Coopers & Lybrand.  Ms. 
Grant also  worked  in  research  and  development,  production,  and  quality 
assurance with Schering Agrochemicals U.K., Wellcome Biotechnologies U.K.  and 
Serono Diagnostics U.K. respectively. Ms. Grant holds an MBA degree from Simon
Fraser University.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one marketed
product, BRINAVESS^TM (vernakalant IV), approved in Europe and other
territories for the rapid conversion of recent onset atrial fibrillation to
sinus rhythm in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at
www.cardiome.com.

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions.
Forward- looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada, Europe, and the
other regions in which we operate; market demand; technological changes that
could impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with, governmental
legislation and regulations; availability of financial reimbursement coverage
from governmental and third-party payers for products and related treatments;
adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy
of our products or products; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to expand commercialization
activities; and any other factors that may affect our performance. In
addition, our business is subject to certain operating risks that may cause
any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete pre-clinical and clinical development of our
products; changes in our business strategy or development plans; intellectual
property matters, including the unenforceability or loss of patent protection
resulting from third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture, market and
sell our products; the availability of capital to finance our activities; and
any other factors described in detail in our filings with the Securities and
Exchange Commission available at www.sec.gov and the Canadian securities
regulatory authorities at www.sedar.com. Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this
cautionary statement. All forward-looking statements and information made
herein are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Contact:

Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Email:ir@cardiome.com
 
Press spacebar to pause and continue. Press esc to stop.